Holly Wardlow,a professor at the University of Toronto, is currently unable to afford a $78,000 monthly medication required to treat a rare liver cancer. This financial crisis follows a recent shift in Ontario's funding policies for drugs sourced outside the province.
The $5.2 billion price tag of Regulation 552
The Ontario government recently modified Regulation 552 of the Health Insurance Act to ensure that only drug treatments with provincial approvals receive funding. According to the report by CTV News Toronto, the health ministry claims that maintaining the previous, more lenient regulations could have cost the Ontario Health Insurance Plan (OHIP) approximately $5.2 billion annually.
Beyond the raw numbers, the province argues that the previous system created a "back door" for global pharmaceutical firms. By restricting funding, the Ontario government aims to force these companies to negotiate directly with the province to secure more competitive pricing for the public system.
Bizengri and the NRG1 fuson cholangiocarcinoma crisis
For Holly Wardlow, these policy shifts are life-threatening. Wardlow suffers from NRG1 fusion cholangiocarcinoma, an exceptionally rare liver cancer that affects only about five people per year in Ontario. To treat it, she uses Bizengri (zenocutuzumab), a drug that has shown success in shrinking her tumour to a size that could eventually allow for curative surgery.
As reported by CTV News Toronto, Wardlow has already spent nearly half a million dollars on the treatment, wiping out her personal savings. While Dr. James Cleary of the Dana Farber Cancer Institute notes that Bizengri offers a significantly better quality of life and higher efficacy than standard chemotherapy, the $78,000 monthly cost has forced Wardlow to rely on family donations and a crowdfunding campaign that has raised just over $57,000.
The Alex Schved court victory and the government's pivot
The tightening of Ontario's drug funding rules appears to be a direct reaction to judicial pressure. Previously, a patient named Alex Schved won a legal battle to secure OHIP funding for a tumour-infiltrating lymphocyte therapy in Florida, which cost US$600,000. The Divisional Court ruled that the government had no valid basis for denying Schved coverage.
This case highlights a growing tension in Canadian healthcare: the conflict between individual patient rights to life-saving innovation and the state's need to manage a finite budget. By implementing the new regulation, the Ontario government has effectively closed the loophole that Schved used, potentially blocking other patients from seeking similar out-of-province remedies.
Why Partner Therapeutics is delaying Health Canada approval
A critical gap in this crisis is the lack of formal provincial approval for Bizengri. While the drug is available via Health Canada's Special Access Program, the manufacturer, Partner Therapeutics, has not sought wider approval. Pritesh Gandhi, the chief development officer at Partner Therapeutics, stated in a letter to Holly Wardlow that the company has no plans to apply for wider Canadian approval for at least two years, as their current focus remains on the United States market.
This leaves patients like Wardlow in a regulatory vacuum.. There remain several unanswered questions regarding the government's transparency: specifically, how the province calculated the $5.2 billion projected cost and why there is no interim bridge for patients with ultra-rare diseases who have no other domestic options. furthermore, the report only presents the government's fiscal justification and the patient's plea, leaving the specific internal deliberations of the Case by Case Review Program at Cancer Care Ontario unknown.
Comments 0